

LITERATURA

1. Gottlieb A. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. *J. Am Acad Dermatol*, 2008;58:851–864.
2. Migkos MP, Somarakis GP, Marketseli TE et al. Epidemiological characteristics of psoriatic arthritis. *Clin Exp Rheumatol* 2019;37:324–332.
3. Prey S. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. *J. Eur. Acad Dermatol Venereol*. 2010;24(Suppl. 2):31–35.
4. Qureshi AA. Psoriatic arthritis and psoriasis: need for a multidisciplinary approach. *Semin Cutan Med Surg*. 2005;24:46–51.
5. Štolfa J. Současný pohled na psoriatickou artritidu, *Acta Medicinæ*, 2012;4:24–29.
6. Štolfa J, Štork J. Psoriatická artritida a psoriáza. 1thed. Maxdorf, 2007:22–42.
7. Wittkowski KM. Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis. *PLoS ONE*. 2011;6:e20279.
8. Wilson FC. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. *Arthritis Rheum*, 2009;61:233–239.
9. Mc Gonagle D. Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease. *J Eur Acad Dermatol. Venereol*. 2009;23(Suppl. 1):9–13.
10. Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. *J Rheumatol*, 2001;28:1842–1846.
11. Štolfa J, Vencovský J, Pavelka K. Doporučené léčebné postupy pro psoriatickou artritidu. *Česká revmatologie* 2016;24:142–152.
12. Gossec L, Baraliakos X, Kerschbaumer A et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update, *Ann Rheum Dis* 2020;79:700–712.
13. Štolfa J. Biologická léčba psoriatické artritidy, *Vnitřní lékařství*, 2018;64(2):127–135.
14. Lie E, van der Heijde D, Uhlig T et al. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. *Ann Rheum Dis* 2010;69:671–676.
15. Mease PJ, Gladman DD, Collier DH et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. *Arthritis Rheumatol* 2019;71:1112–1124.
16. Nash P, Kirkham B, Okada M et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. *The Lancet* 2017;389:2317–2327.
17. McInnes IB, Kavanaugh A, Gottlieb AB et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. *Lancet* 2013;382:780–789.
18. Kristensen LE, Lie E, Jacobsson LTH et al. Effectiveness and feasibility associated with switching to a second or third TNF inhibitor in patients with psoriatic arthritis: a cohort study from southern Sweden. *J Rheumatol* 2016;43:81–87.
19. Mease P, Hall S, FitzGerald O et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. *N Engl J Med* 2017;377:1537–1550.
20. Gladman D, Rigby W, Azevedo VF et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. *N Engl J Med* 2017;377:1525–1536.